Dr. Dana Borcherding, a senior scientist in the laboratory of Dr. Angela Hirbe, recently found that the combination of two drugs targeting different growth control pathways in MPNST cells dramatically decreased tumor growth in mice. In their studies, they combined a TYK2 inhibitor with a MEK inhibitor to achieve this dramatic effect with minimal toxicity. Dr. Hirbe and her team hope to bring this combination therapy to a clinical trial for people with MPNST.
This work was published in Clinical Cancer Research and was funded by a CDRMP NFRP grant (W81XWH-20-1-0148).